Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6456478

Cc1cnc(N[C@H]2CC[C@@H](NC(=O)c3ccc(F)c(F)c3)CC2)nc1NC1CC1.O=C(O)C(F)(F)F

nearest known ligand 0.69

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 13/20 0.69
ADRA2A P08913 6/20 0.54
HRH1 P35367 6/20 0.54
HTR2B P41595 6/20 0.54
ADRA1A P35348 4/20 0.54
HTR1A P08908 1/20 0.52
NPY5R Q15761 1/20 0.52
AURKA O14965 2/20 0.46
AURKB Q96GD4 2/20 0.46
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
GPR6 P46095 1/20 0.45
CSNK2A1 P68400 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
SYK P43405 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6831616 1.00 MCHR1 (0.69) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6455569 0.94 MCHR1 (0.67) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6833473 0.94 MCHR1 (0.67) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL5819952 0.94 MCHR1 (0.76) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6456496 0.92 MCHR1 (0.65) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6831115 0.92 MCHR1 (0.65) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6459409 0.92 MCHR1 (0.64) MCHR1ADRA2AHRH1HTR2BADRA1A
Trifluoroacetic Acid SCHEMBL6456457 0.88 MCHR1 (0.66) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL4258540 0.82 MCHR1 (0.71) MCHR1ADRA2AHRH1HTR2BADRA1A
SCHEMBL4258534 0.82 MCHR1 (0.71) MCHR1ADRA2AHRH1HTR2BADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101475528-A Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO LTD (JP) 2009-07-08 CN disclosed
CN-100451004-C Pyrimidine derivatives ARENA PHARM INC (JP) 2009-01-14 CN disclosed
CN-1798736-A Novel quinoline, tetrahydroquinazoline and pyrimidine derivatives and methods of treatment related to their use ARENA PHARM INC (JP) 2006-07-05 CN disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 MCHR1 2/4885ADRA2A 117/4885HRH1 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.